Lonza expands ADC platform and Lonza Group stock costs EUR 615.60
Published on 10/13/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- Lonza announced an exclusive CDK7 inhibitor agreement with Qurient on October 12, 2026.
- The SYN-duo CC platform combines exatecan with a CDK7 inhibitor for dual-payload antibody-drug conjugates.
- Half-Year 2026 sales reached CHF 3.4 billion and CORE EBITDA reached CHF 1.2 billion.
- Lonza Group stock was EUR 615.60 at Lang & Schwarz on October 13, 2026 at 9:20 a.m. CEST.
Lonza Group (CH0013841017) was trading at EUR 615.60 at Lang & Schwarz on October 13, 2026 at 9:20 a.m. CEST. On October 12, 2026, Lonza announced an exclusive agreement with Qurient to use CDK7 inhibitors in dual-payload antibody-drug conjugates, according to EQS News.
What does the ADC deal change?
The agreement adds Qurient's CDK7 inhibitor technology to Lonza's ADC toolbox. Its first format, SYN-duo CC, combines two active components, exatecan and a CDK7 inhibitor, in an off-the-shelf linker-payload for dual-payload ADC development, the company said in its October 12, 2026 release.
The commercial terms were not quantified in the release, so the immediate value is technological rather than a reported revenue contribution. Lonza can also use its platform to create further combinations involving Qurient's inhibitor and other payloads.
Three dated operating milestones
On July 22, 2026, Lonza reported Half-Year 2026 sales of CHF 3.4 billion and CORE EBITDA of CHF 1.2 billion while upgrading its full-year margin outlook, according to EQS News. On September 10, 2026, the company announced an additional commercial spray-drying facility in Bend, Oregon, as part of its US manufacturing expansion.
On September 30, 2026, Lonza nominated Pearl Huang as an independent board member. The company said eight new board members had joined since 2024, according to Financial Times.
Next dates carry the test
Lonza's next substantiated company dates are October 14, 2026, for its Capital Markets Day in Vacaville and its qualitative third-quarter 2026 business update, according to Aktiencheck. Those updates can show whether the new ADC offering is translating into customer activity beyond the initial technology announcement.
Stock price and trading status
Lonza Group stock was trading at EUR 615.60 at Lang & Schwarz on October 13, 2026 at 9:20 a.m. CEST. The current quote gives investors a live market reference while the October 14 company events provide the next dated test of strategy and execution.
The further course of trading is shown by the continuously updated real-time quote of Lonza Group stock.
Lonza Group stock facts
- Company: Lonza Group AG
- ISIN: CH0013841017
- Ticker: LONN
- Primary exchange: SIX Swiss Exchange
- Price Lang & Schwarz as of October 13, 2026, 9:20 a.m. CEST: EUR 615.60
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report SMI.
